CCCiarán Campbell

Ciarán Campbell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ciarán Campbell has a total of 50 co-authors. Here are the top co-authors by number of shared publications:

  • Gianpiero L. Cavalleri

    School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland

    2 shared publications
  • Holger Lerche

    Department of Neurology & Epileptology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany

    2 shared publications
  • Anne Molloy

    Department of Medical Gerontology, School of Medicine, Trinity College Dublin, Dublin 2, Republic of Ireland

    1 shared publication
  • Berge A. Minassian

    Department of Pediatrics, Hospital for Sick Children and University of Toronto, Toronto, Canada

    1 shared publication
  • Bobby P. Koeleman

    Division of Neurosciences Universitair Medisch Centrum Utrecht Utrecht The Netherlands

    1 shared publication
  • Caragh Stapleton

    Department of Pharmacy and Biomolecular Science RCSI Dublin Dublin Ireland

    1 shared publication

Latest Publications

  • Open Access

    The role of common genetic variation in presumed monogenic epilepsies

    by Ciarán Campbell, Costin Leu, Yen-Chen Anne Feng, Stefan Wolking, Claudia Moreau, Colin Ellis, Shiva Ganesan, Helena Martins, Karen Oliver, Isabelle Boothman, et al.


  • Open Access

    A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam

    by Ciarán Campbell, Mark McCormack, Sonn Patel, Caragh Stapleton, Dheeraj Bobbili, Roland Krause, Chantal Depondt, Graeme J. Sills, Bobby P. Koeleman, Pasquale Striano, et al.

    Objective: Levetiracetam (LEV) is an effective antiseizure medicine, but 10%–20% of people treated with LEV report psychiatric side‐effects, and up to 1% may have psychotic episodes. Pharmacogenomic predictors of these adverse drug reactions (ADRs) have yet to be identified. We sought to determine the contribution of both common and rare genetic variation to psychiatric and behavioral ADRs associated with LEV.Methods: This case‐control study compared cases of LEV‐associated behavioral disorder (n = 149) or psychotic reaction (n = 37) to LEV‐exposed people with no history of psychiatric ADRs (n = 920). All samples were of European ancestry. We performed genome‐wide association study (GWAS) analysis comparing those with LEV ADRs to controls. We estimated the polygenic risk scores (PRS) for schizophrenia and compared cases with LEV‐associated psychotic reaction to controls. Rare variant burden analysis was performed using exome sequence data of cases with psychotic reactions (n = 18) and controls (n = 122).Results: Univariate GWAS found no significant associations with either LEV‐associated behavioural disorder or LEV‐psychotic reaction. PRS analysis showed that cases of LEV‐associated psychotic reaction had an increased PRS for schizophrenia relative to contr ols (p = .0097, estimate = .4886). The rare‐variant analysis found no evidence of an increased burden of rare genetic variants in people who had experienced LEV‐associated psychotic reaction relative to controls.Significance: The polygenic burden for schizophrenia is a risk factor for LEV‐associated psychotic reaction. To assess the clinical utility of PRS as a predictor, it should be tested in an independent and ideally prospective cohort. Larger sample sizes are required for the identification of significant univariate common genetic signals or rare genetic signals associated with psychiatric LEV ADRs.